OBJECTIVE: To estimate the cost-effectiveness of three @entity5626 ( @entity25928 , @entity11794 , and @entity1331 ) and generic @entity2380 in the treatment of nonneutropenic adult @entity1 with @entity4963 and/or @entity3 in intensive care units in Spain. MATERIALS AND METHODS: A decision-tree model was applied. The success and safety (hepatic and renal adverse effects) of first-line treatments were obtained from meta-analyses and systematic reviews of clinical trials. In the case of failure, a second-line treatment (liposomal @entity2379 after the @entity5626 , or one of the @entity5626 after @entity2380 ) was administered. The duration of the treatments (14 days total) was established by a panel of clinical experts using the Delphi method and according to @entity166 Society of America guidelines. The cost of the medications and renal @entity137 were considered. Deterministic and probabilistic sensitivity analysis using Monte Carlo simulations were carried out. RESULTS: The total cost of the treatment of @entity4963 and/or @entity3 with @entity25928 , @entity11794 , @entity1331 , and @entity2380 was    5,483,    5,968,    6,231, and    2,088, respectively. @entity25928 was the dominant treatment (more effective, less expensive) compared to @entity1331 and @entity11794 . The cost of achieving one more @entity1 successfully treated with @entity25928 , @entity11794 , and @entity1331 compared to @entity2380 was    17,199,    23,962, and    27,339, respectively. The result remained stable, despite modification of the duration of the first-line and second-line treatments, as well as most of the dosing regimens. The probabilistic analysis also remained stable. CONCLUSION: In accordance with this economic study, @entity25928 would produce savings and would be the dominant treatment compared with @entity1331 and @entity11794 in nonneutropenic adult @entity1 with @entity4963 and/or @entity3 in intensive care units in Spain.

Cost-effectiveness of three @entity5626 and @entity2380 in the treatment of @entity4963 and/or XXXX in nonneutropenic adult @entity1 .

@entity1331 :: ('MESH:C121905', 'Chemical') :: ['micafungin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity25928 :: ('MESH:C102786', 'Chemical') :: ['anidulafungin', 'Anidulafungin'] @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B'] @entity2380 :: ('MESH:D015725', 'Chemical') :: ['fluconazole'] @entity4963 :: ('MESH:D058387', 'Disease') :: ['candidemia'] @entity5626 :: ('MESH:D054714', 'Chemical') :: ['echinocandins'] @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive candidiasis'] @entity166 :: ('MESH:D003141', 'Disease') :: ['Infectious Diseases'] @entity11794 :: ('MESH:C105417', 'Chemical') :: ['caspofungin']
@entity3 :: (MESH:D009362,Disease) :: ['invasive candidiasis']
